THERAPY DOSSIER · th-c045f73fab29

Yupingfeng granules (Chinese herbal formulation)

Nutraceutical

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: Chemical/toxin
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 2

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

NCT06608017 ↗PHASE2/PHASE3recruiting

Effects of Yupingfeng Powder with variation for the treatment of allergic rhinitis: a randomised controlled trial

Allergic Rhinitis

Enrolment: 140 · Results not recorded

NCT04976023 ↗PHASE2completed

Effects of Yupingfeng Powder with variation for the treatment of allergic rhinitis: a randomised controlled trial

Allergic Rhinitis

Enrolment: 58 · Results not recorded

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 32186134 ↗2018Reported benefit

Effect of Yupingfeng granules on the skin barrier in atopic dermatitis mice models.

MouseChemical/toxinBALB/cMaleAfter induction of atopic dermatitis lesions

Model: Acute atopic dermatitis-like skin lesions induced with 2,4-dinitrochlorobenzene (DNCB)

Yupingfeng granules accelerated wound healing (63.64 percent versus 31.82 percent for placebo, P less than 0.01) and significantly reduced skin thickness, skin weight and trans-epidermal water loss while downregulating aquaporin 3.

Extraction: extract · Supplied extraction confidence: 0.55. Machine-extracted fields require source verification.

Loading the evidence…